Related Experiment Video
Updated: Jun 18, 2026

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
Published on: October 31, 2010
Monitoring the performance of New Zealand's National Cervical Screening Programme through data linkage
Hazel Lewis1, Li-Chia Yeh, Bobby Almendral
1National Screening Unit, Ministry of Health, P O Box 5013, Wellington, New Zealand. hazel_lewis@moh.govt.nz
Aim:
To describe the method developed by the National Cervical Screening Programme (NCSP) for review of cases of cervical cancer; present results from the first 4 years of the review and compare these results with those of the earlier New Zealand Cervical Cancer Audit.
Methods:
Linkage of cervical cancer registrations from the New Zealand Cancer Registry to smear histories from the NCSP Register via the National Health Index, for the 4-year period 2003-06.
Results:
A total of 625 women were registered with cervical cancer from 2003-06, of whom 438 were eligible for linkage (women diagnosed with squamous or adenosquamous cervical cancer at <80 years of age). Of these 438 eligible cases, 348 were histologically invasive and 90 were microinvasive. Unlike histological stage, clinical FIGO stage was missing in approximately 50%. Linkage to screening history revealed that 202 of the 438 eligible women (46%) had never been enrolled in the NCSP; 137 (31%) were enrolled but had only been infrequently or irregularly screened; and 85 (20%) developed cancer despite regular screening (data were missing for 3 women). These results were similar to those found in the New Zealand Cervical Cancer Audit, covering the period 2000-2002.
Conclusions:
Ongoing linkage of cancer data to screening data can be used to monitor the performance of the NCSP. Our finding that 80% of potentially preventable cervical cancers involve women who are not enrolled in the Programme or who have been only infrequently and irregularly screened, confirms that improving Programme coverage (currently around 72%) remains a priority. Further investigation (phase 2) is required for the small number of women who develop cervical cancer despite regular screening (average of 21 per year, or approximately 20% of eligible cases), to distinguish interval cancers from possible Programme quality issues.